Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Incyte Corporation (INCY) Market Cap & Valuation Ratios

Incyte Corporation (INCY) has a market cap of $23.5B, a trailing P/E of 14.7 and a price-to-sales ratio of 4.0, with earnings according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

INCYIncyte CorporationFollow INCY — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
23.5B
P/E TTM
14.7
Dividend yield
—
52-week
—
Next earnings
29 Oct, in 5 days

Peers

biotechnology · nearest by market cap · trailing 12 months
CompanyMkt cap, $BP/EEV/SalesEV/EBITDAFCF yieldRev. growthOp. marginROIC
INCY2314.73.310.48.2%+27%31%64%
RVMD40———-3.1%——-71%
RPRX3734.017.729.68.1%+10%60%10%
ALNY3041.65.826.22.7%+95%21%173%
ROIV26———-3.1%-68%—-20%
INSM20—17.4—-4.0%+186%-74%-133%
EXEL1620.36.215.27.3%+9%40%47%
ASND15————+113%25%11%
HALO1436.69.826.55.7%+41%36%22%
JAZZ1414.63.610.310.3%+13%19%9%
BBIO13—21.3—-3.2%+202%-70%—
Median of these 1034.09.826.22.7%+41%23%10%

P/E 14.7 vs. a peer median of 34.0; EV/Sales 3.3 vs. 9.8. INCY's own P/E sits at the 5th percentile of its history.

Growth vs. price

each dot a company · hover or tap for values
1020500%+25%+50%+75%+100%revenue growth, TTM →P/E (log)INCYRPRXALNYEXELHALOJAZZ

RVMD and ROIV and INSM and ASND and BBIO have no P/E (earnings not positive) and are left out · hover or tap a dot for values.

Incyte Corporation — questions

What is Incyte Corporation's market cap?
$23.5B.
What is Incyte Corporation's P/E ratio?
14.7 on trailing twelve-month earnings to 2026-06-30.
What is Incyte Corporation's price-to-sales ratio?
4.0.

Every figure on this page comes from Incyte Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.